Plasmonic Inactivation of Virus and Mycoplasma Contaminants

病毒和支原体污染物的等离子体灭活

• 批准号: 10640258
• 负责人: SHYAMSUNDER ERRAMILLI
• 金额: $ 33万
• 依托单位: BOSTON UNIVERSITY (CHARLES RIVER CAMPUS)
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-01 至 2025-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10640258
• 关键词: Address; Antibodies; Bacteria; Benchmarking; Biological; Biological Products; Bioreactors; Biotechnology; COVID-19 pandemic; Categories; Cell Culture Techniques; Cell Line; Cells; Chemicals; Clinical; Containment; Dangerousness; Development; Diameter; Disease; Disinfectants; Electromagnetic Fields; Electromagnetics; Electronics; Endotoxins; Ensure; Excision; Filtration; Generations; Goals; Gold; Guidelines; Health; Human; Human body; Immunology procedure; Industrialization; Industry; Industry Standard; Infrared Rays; Investigation; Laboratories; Lasers; Light; Magnetism; Mediating; Membrane; Methods; Microbe; Molecular; Monoclonal Antibodies; Mycoplasma; Nanostructures; Nanotechnology; Nucleosome Core Particle; Optics; Pathway interactions; Patient-Focused Outcomes; Pharmaceutical Preparations; Pharmacologic Substance; Photochemistry; Principal Investigator; Process; Production; Property; Proteins; Public Health; Radiation; Reactive Oxygen Species; Reproducibility; Risk; Sampling; Scheme; Shapes; Specificity; Sterilization; Technology; Temperature; Time; Tissue Sample; Tissues; Treatment Efficacy; Ultrafiltration; Ultraviolet Rays; Viral; Virion; Virus; Virus Inactivation; Work; absorption; bactericide; cost; emerging antibiotic resistance; fabrication; flexibility; fundamental research; improved; innovation; irradiation; magnetic field; manufacture; manufacturing process; manufacturing technology; microbial; monoclonal antibody production; nanomaterials; nanoparticle; nanoplasmonic; pathogen; pathogenic microbe; photonics; plasmonics; point of care; pressure; prevent; programs; response; superparamagnetism; ultraviolet irradiation

SUMMARY Biological pharmaceuticals, or “biologics”, are among the most important pharmaceuticals in development today, and their safe manufacture is absolutely crucial for human health. A major problem faced by operators of bioreactors, at both the laboratory scale and industrial scale, is microbial contamination as an integral risk of any process that derives from live cell lines. The fundamental concern is to ensure that contaminated biologics are not injected into the human body. To warrant contamination free biologics a terminal sterilization is often necessary. The central challenge in this step is the inactivation or removal of microbial contaminates without causing harm to the precious biologics. This work focuses on antibodies as representative biologics. Especially for viral and mycoplasma contaminations the terminal sterilization step remains challenging due to the small size of the pathogens. The industry standard today is removal through passive filtration using filter membranes with pore diameters smaller or of the same size as the virus particles. This approach requires, however, long processing times associated with high costs. Furthermore, ultrafiltration can induce antibody self-association and is not compatible with emerging flexible, small-scale, point-of-care biologics fabrication technologies. The need for new selective microbe inactivation strategies is also not limited to the field of biologics fabrication. The Covid19 pandemic has recently illustrated the need for reliable virus inactivation strategies that selectively act on the virus in tissues but not on proteins, for instance, to allow immunological assays of infected samples outside of high containment laboratories. Light has sterilization properties, and UV-light has long been used to inactivate a broad range of microbial pathogens. Unfortunately, it lacks specificity and also damages precious biologics through reactive photochemistries driven by molecular absorptions in the UV range of the electromagnetic spectrum. To overcome the shortcomings of both ultrafiltration and UV-irradiation as microbe inactivation strategies, this proposal develops a plasmonically enhanced photonic inactivation method that utilizes near-infrared (NIR) light for the selective inactivation of viruses and mycoplasma. As NIR radiation does not overlap with molecular absorptions, the collateral damage on biologics is minimal. The proposed work will reveal the fundamental working principles underlying plasmonic pathogen inactivation and implement magnetic plasmonic nanoparticles (NPs) that allow for an easy, contact-free removal of the nanomaterials from the samples after sterilization. The specific aims of this application are to: Aim 1: Achieve Reliable Virus Inactivation with NIR Light through Plasmonic Enhancement Aim 2: Demonstrate a Plasmon-Enhancement Strategy for Mycoplasma Inactivation with NIR Light Aim 3: Demonstrate Scalable Clearance of Virus and Mycoplasma with Magnetic Plasmonic NPs

总结 生物制药，或“生物制品”，是最重要的药物开发之一 安全生产对人类健康绝对至关重要。运营商面临的一大难题 生物反应器，在实验室规模和工业规模，是微生物污染的一个整体风险， 任何源自活细胞系的过程。最根本的问题是确保受污染的生物制品 不会被注入人体。为了保证无污染的生物制品，通常 必要这一步骤的核心挑战是灭活或去除微生物污染物， 对珍贵的生物制品造成伤害。这项工作的重点是抗体作为代表性的生物制品。尤其 对于病毒和支原体污染，由于小的 病原体的大小。今天的工业标准是通过使用过滤膜的被动过滤来去除 孔径小于病毒颗粒或与病毒颗粒大小相同。然而，这种方法需要很长的时间。 与高成本相关的处理时间。此外，超滤可诱导抗体自结合 并且与新兴的灵活的、小规模的、护理点生物制剂制造技术不兼容。的 对新的选择性微生物灭活策略的需要也不限于生物制品制造领域。的 Covid 19大流行最近表明需要可靠的病毒灭活策略， 例如，对组织中的病毒而不是蛋白质进行免疫分析， 隔离实验室之外的地方光具有杀菌特性，紫外线长期以来一直被用于 包括多种微生物病原体。不幸的是，它缺乏特异性，也损害了宝贵的 生物制剂通过在紫外线范围内的分子吸收驱动的反应性光化学反应， 电磁频谱为了克服超滤法和紫外线照射法作为微生物处理的缺点， 灭活策略，该建议开发了等离子体增强的光子灭活方法， 利用近红外（NIR）光选择性灭活病毒和支原体。就像近红外辐射一样 不与分子排斥重叠，对生物制品的附带损害是最小的。拟议的工作将 揭示等离子体病原体灭活的基本工作原理，并实现磁 等离子体纳米颗粒（NP），其允许从纳米材料中容易地、无接触地去除纳米材料。 灭菌后的样品。本申请的具体目的是： 目标1：通过等离子体增强实现近红外光的可靠病毒灭活 目的2：证明用NIR光灭活支原体的等离子体增强策略 目的3：证明用磁性等离子体纳米颗粒可扩展地清除病毒和支原体

项目成果

Thermal transport across membranes and the Kapitza length from photothermal microscopy

跨膜热传输和光热显微镜的 Kapitza 长度

• DOI: 10.1007/s10867-023-09636-0
• 发表时间: 2023
• 期刊: Journal of Biological Physics
• 影响因子: 1.8
• 作者: Samolis, Panagis D.;Sander, Michelle Y.;Hong, Mi K.;Erramilli, Shyamsunder;Narayan, Onuttom
• 通讯作者: Narayan, Onuttom